INT173575

Context Info Confidence 0.35 First Reported 2003 Last Reported 2008 Negated 0 Speculated 1 Reported most in Body Documents 2 Total Number 6 Disease Relevance 0.79 Pain Relevance 0.36

peptidase activity (MMP13) extracellular space (MMP13) extracellular region (MMP13) Golgi apparatus (MMP13) proteinaceous extracellular matrix (MMP13) lysosome (MMP13)

Anatomy Link Frequency proximal 1 MMP13 (Homo sapiens)

Pain Link Frequency Relevance Heat Osteoarthritis 74 97.08 metalloproteinase 114 66.32 agonist 4 50.00 rheumatoid arthritis 35 46.08 Inflammatory stimuli 4 41.08 Potency 5 37.44 Arthritis 17 21.32 Inflammation 46 7.92 cytokine 34 5.72 Pain 7 5.00

Disease Link Frequency Relevance Heat Osteoarthritis 76 97.08 Frailty 1 74.08 Cancer 19 62.56 Osteoporosis 10 50.00 Rheumatoid Arthritis 35 46.08 Hypercalcemia 27 44.16 INFLAMMATION 53 40.76 Stomach Cancer 1 37.16 Granuloma 1 24.40 Acne 1 22.64

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

binding at the DR-1/AP-1 site of the endogenous MMP-1 and MMP-13 promoters in genomic DNA.

MMP-13 Binding (binding) of

1) Confidence 0.35 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0 Pain Relevance 0

reduced expression of both constructs, which does not reflect the response of endogenous MMP-1 and MMP-13, whose expression is induced by IL-1?

MMP-13 Binding (endogenous) of

2) Confidence 0.35 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0 Pain Relevance 0

Combined treatment with rosiglitazone and LG268 further reduces MMP-1 and MMP-13 mRNA and hnRNA

MMP-13 Binding (mRNA) of

3) Confidence 0.35 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0 Pain Relevance 0.07

were binding to the DR-1/AP-1 site in the MMP-1 and MMP-13 proximal promoters, this DNA element may also be responsive to treatment with combinations of LG268 and rosiglitazone.

MMP-13 Binding (binding) of in proximal

4) Confidence 0.35 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656243 Disease Relevance 0 Pain Relevance 0

At the end of the incubation period, the conditioned medium served for MMP-13 determination, and cathepsin K determination was carried out on the cell lysates.

MMP-13 Binding (determination) of

5) Confidence 0.14 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2483463 Disease Relevance 0 Pain Relevance 0

Another inhibitor, tanomastat (BAY 12–9566; Bayer Corporation, West Haven, CT, USA), targets MMP-3, MMP-2, MMP-8, MMP-9 and MMP-13, with low activity against MMP-1, and was proposed for the treatment of OA.

MMP-13 Spec (proposed) Binding (targets) of associated with osteoarthritis

6) Confidence 0.09 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC154424 Disease Relevance 0.79 Pain Relevance 0.29

General Comments

This test has worked.